Edarbyclor

The active ingredients in Edarbyclor are azilsartan medoxomil and chlorthalidone. Azilsartan is an ARB (angiotensin receptor blocker) that prevents angiotensin II from tightening the blood vessels. When this hormone is blocked, the blood vessels relax, allowing blood to flow more easily and helping lower blood pressure. Chlorthalidone is a thiazide diuretic that helps the kidneys remove excess water and salt from the body. This reduces fluid buildup, helping lower blood pressure and improve blood pressure goals.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Edarbyclor. However, the following is a synopsis of the general guidelines for the use of Edarbyclor:

• Take Edarbyclor once daily at the same time each day.
• Swallow the tablet whole with or without food.
• If you become ill and cannot keep down fluids, skip your dose of Edarbyclor as it can lead to serious side effects when used during dehydration.
• Drink adequate fluids unless your healthcare provider instructs otherwise.
• Avoid Edarbyclor if you cannot urinate (anuria).
• Your doctor may need to monitor your renal function (creatinine), sodium, and potassium levels while you take this medication.

Some mild or common side effects of Edarbyclor include:

• Dizziness or lightheadedness.
• Dry mouth.
• Constipation.
• Low blood pressure (hypotension).

Some individuals may experience serious side effects while using Edarbyclor. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• Signs of kidney problems include changes in urination or swelling.
• Severe low blood pressure or fainting.
• Allergic reactions such as swelling, hives, or trouble breathing.
• Electrolyte changes, such as hypokalemia. Symptoms include a fast heartbeat, weakness, low energy, muscle pain or cramps, less urination than usual, nausea, or vomiting.
• Worsening gout.

These are not all of the possible adverse reactions of Edarbyclor. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Edarbyclor, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including:

Kidney disease or renal impairment.

Liver issues.

Gout or a history of gout attacks.

Low blood pressure or dehydration.

Electrolyte disorders, such as low potassium or low sodium.

Congestive heart failure or heart attack history.

Diabetes, especially if taking aliskiren.

Anuria (inability to produce urine).

Allergy to azilsartan, chlorthalidone, or sulfonamide-containing drugs.

Taking it along with Tekturna (aliskiren) if you have diabetes.

Edarbyclor begins lowering blood pressure within hours, with the full effect reached over several weeks.

When Edarbyclor is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

NSAIDs such as ibuprofen or naproxen may affect kidney function.

ACE inhibitors, as they share a similar mechanism to azilsartan.

Lithium, as levels may rise and cause toxicity.

It is available in fixed-dose combination tablets containing either 40/12.5mg or 40/25mg of azilsartan medoxomil/chlorthalidone.

It should be stored at room temperature, away from the reach of children or pets.

Edarbyclor is manufactured by Takeda Pharmaceuticals.

No, but both active ingredients are available as separate dosage forms, such as Edarbi, which contains azilsartan medoxomil.

Do not stop taking Edarbyclor without speaking to your healthcare provider. Stopping suddenly may raise your blood pressure or increase the risk of a heart attack or stroke.

Edarbyclor can harm an unborn baby and must be stopped immediately if pregnancy occurs.

Chlorthalidone may pass into breastmilk, and your healthcare provider will determine whether the benefits outweigh potential risks.

Talk to your doctor if you are already breastfeeding or if you have any plans to breastfeed. They will know or recommend what is best for you.